Moderna, Inc. (NASDAQ:MRNA) Insider Shannon Thyme Klinger Sells 557 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 557 shares of the firm’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $107.22, for a total transaction of $59,721.54. Following the completion of the sale, the insider now owns 7,215 shares in the company, valued at approximately $773,592.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shannon Thyme Klinger also recently made the following trade(s):

• On Tuesday, September 5th, Shannon Thyme Klinger sold 115 shares of Moderna stock. The stock was sold at an average price of $111.44, for a total value of $12,815.60.

Moderna Stock Down 1.7 %

Shares of NASDAQ MRNA opened at $105.80 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.16 and a current ratio of 3.39. Moderna, Inc. has a 52 week low of $95.02 and a 52 week high of $217.25. The stock has a market capitalization of $40.27 billion, a P/E ratio of 39.04 and a beta of 1.63. The stock’s fifty day moving average is $113.70 and its 200 day moving average is $128.71.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($3.62) EPS for the quarter, topping analysts’ consensus estimates of ($3.84) by $0.22. The company had revenue of $344.00 million for the quarter, compared to analysts’ expectations of $307.67 million. Moderna had a return on equity of 6.62% and a net margin of 11.33%. Moderna’s revenue was down 92.8% on a year-over-year basis. During the same quarter last year, the business earned $5.24 earnings per share. Sell-side analysts forecast that Moderna, Inc. will post -4.31 earnings per share for the current fiscal year.

Institutional Trading of Moderna

Several large investors have recently bought and sold shares of the business. Triatomic Management LP boosted its stake in Moderna by 19.3% in the second quarter. Triatomic Management LP now owns 5,250 shares of the company’s stock valued at $638,000 after buying an additional 850 shares in the last quarter. Portside Wealth Group LLC acquired a new stake in shares of Moderna during the second quarter valued at about $1,030,000. Manhattan West Asset Management LLC boosted its stake in shares of Moderna by 116.9% during the second quarter. Manhattan West Asset Management LLC now owns 11,975 shares of the company’s stock valued at $1,455,000 after purchasing an additional 6,455 shares in the last quarter. Brown Shipley& Co Ltd acquired a new stake in shares of Moderna during the second quarter valued at about $18,920,000. Finally, Virginia Retirement Systems ET AL acquired a new stake in shares of Moderna during the second quarter valued at about $9,356,000. 64.51% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on MRNA. William Blair began coverage on shares of Moderna in a research note on Monday, July 24th. They set a “market perform” rating and a $136.28 price target on the stock. Bank of America reduced their target price on shares of Moderna from $175.00 to $150.00 and set a “neutral” rating on the stock in a research note on Friday, August 4th. Jefferies Financial Group reduced their target price on shares of Moderna from $275.00 to $175.00 in a research note on Friday, August 4th. UBS Group upgraded shares of Moderna from a “neutral” rating to a “buy” rating and reduced their target price for the company from $221.00 to $191.00 in a research note on Monday, June 26th. Finally, Morgan Stanley reduced their target price on shares of Moderna from $128.00 to $123.00 and set an “equal weight” rating on the stock in a research note on Friday, August 4th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $156.07.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.